Relay Therapeutics (company)

Relay Therapeutics (company)

Relay Therapeutics is a Cambridge, Massachusetts-based developer of an allosteric drug-discover platform that is intended to apply computational techniques to protein motion.

Relay Therapeutics is a precision oncology company that uses protein motion to develop cancer therapeutics. It was founded in 2016 by David E. Shaw, Dorothee Kern, Mark Murcko, and Matthew Jacobson. Relay Therapeutics started its initial public offering (IPO) on July 20th, 2020. Prior to that, the company raised funding until its Series C round, receiving financing from investors such as SoftBank, Foresite Capital, and Tavistock Group. Relay Therapeutics is headquartered in Cambridge, Massachusetts, United States.

Product and Service

Relay Therapeutics has its own proprietary drug development platform called Dynamo, which integrates long-timescale molecular dynamics simulations and machine learning together with room-temperature crystallography and cryoEM. Dynamo also utilizes an approach that Relay Therapeutics called as motion-based drug design (MBDD), which is a form of drug discovery process that allows for long-timescale simulations of protein dynamics. Through these techniques and existing genome data, Relay Therapeutics is able to develop compounds that target specific genes, with recently developed drugs aimed at SHP-2, FGFR2, and PI3Kα.

Timeline

December 2018
Relay Therapeutics raises a $400,000,000 series C round from Biotechnology Value Fund, Casdin Capital, D. E. Shaw Research, EcoR1 Capital, Foresite Capital, GV, Perceptive Advisors, SoftBank Vision Fund and Tavistock Group.
December 2017
Relay Therapeutics raises a $63,000,000 series B round from Alexandria Venture Investments, Biotechnology Value Fund, Casdin Capital, EcoR1 Capital, GV, Section 32 and Third Rock Ventures.
September 2016
Relay Therapeutics raises a $57,000,000 series A round from Third Rock Ventures.

Funding rounds

Funding round
Funding type
Funding round amount (USD)
Funding round date
Investment
Relay Therapeutics funding round, December 2018
400,000,000
December 2018
3 Results
Results per page:
Page 1 of 1

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Melanie Senior
April 1, 2021
Nature Biotechnology
Private biotech firms are awash with funding, raising record-breaking sums in 2020. Melanie Senior reports.

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.